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Abstract
BACKGROUND
Transjugular intrahepatic portosystemic shunts (TIPS) can alleviate complications
of portal hypertension such as ascites and variceal bleeding by decreasing the
portosystemic gradient. In limited clinical situations, parallel TIPS may be only
solution to alleviate either variceal bleeding or ascites secondary to portal
hypertension when the primary TIPS fails to do so. Data specifically addressing
the use of this partially polytetrafluoroethylene covered nitinol stent (Viatorr®) is
largely lacking despite Viatorr® being the current gold standard for modern TIPS
placement.
CASE SUMMARY
All three patients had portal hypertension and already had a primary Viatorr®
TIPS placed previously. All patients have undergone failed endoscopy to manage
acute variceal bleeding before referral for a parallel stent (PS). PS were placed in
patients presenting with recurrent variceal bleeding despite existence of a widely
patent primary TIPS. Primary stent patency was verified with either Doppler
ultrasound or intra-procedural TIPS stent venography. Doppler ultrasound
follow-up imaging demonstrated complete patency of both primary and parallel
TIPS. All three patients did well on clinical follow-up of up to six months and no
major complications were recorded. A review of existing literature on the role of
PS in the management of portal hypertension complications is discussed. There
are three case reports of use of primary and PS Viatorr® stents placement, only
one of which is in a patient with gastrointestinal variceal bleeding despite a
patent primary Viatorr® TIPS.
CONCLUSION
Viatorr® PS placement in the management of variceal hemorrhage is feasible with
promising short term patency and clinical follow-up data.
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Core tip: To our knowledge, we are first to report a three-case series with 6-month
follow-up data using Viatorr® for both primary transjugular intrahepatic portosystemic
shunt (TIPS) and parallel TIPS placement for the management of recurrent upper
gastrointestinal variceal hemorrhage. Although, parallel TIPS placement has been
previously reported, it was largely using bare metal stents and/or fully covered stents.
Data regarding the use of the partially polytetrafluoroethylene-covered nitinol stent
(Viatorr®) in parallel TIPS placement is largely lacking despite this device being the
current gold standard for TIPS placement.
Citation: Raissi D, Yu Q, Nisiewicz M, Krohmer S. Parallel transjugular intrahepatic
portosystemic shunt with Viatorr® stents for primary TIPS insufficiency: Case series and
review of literature . World J Hepatol 2019; 11(2): 217-225
URL: https://www.wjgnet.com/1948-5182/full/v11/i2/217.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i2.217
INTRODUCTION
Gastroesophageal varices and ascites are common complications of portal hyperten-
sion and cirrhosis. It is estimated that the mortality during the first episode of acute
upper gastrointestinal variceal bleeding in cirrhotic patients is between 15%-30%[1-3],
whereas the mortality rates of ascites in those patients increases from 15% to 44%
between  one-year  and  five-year  follow-ups [ 4 , 5 ].  Transjugular  intrahepatic
portosystemic shunt (TIPS) can alleviate these two complications by decreasing the
portosystemic gradient. This is achieved by decompressing the portal venous system
directly via a stent supported shunt into the systemic circulation[6-9]. A previous study
suggested an association between the early use of TIPS in cirrhotic patients with
variceal bleeding with a reduction in mortality[10]. Additionally, according to a meta-
analysis of four randomized trials, cirrhotic patients with recurring ascites that have
received TIPS demonstrated a higher transplant-free survival compared to those
receiving paracentesis at 6, 12, 24, and 36 months: 75.1% vs 65.3%, 63.1% vs 52.5%,
49.0% vs 35.2%, and 38.1% vs 28.7% (P = 0.035)[11]. Yet, one complication of TIPS was
shunt dysfunction, which could be manifested by the persistence or recurrence of
ascites, variceal bleeding after the initial procedure, unsuccessful reduction of portal
venous pressure, elevated portosystemic gradient, and decreased mid-shunt velocity
on  Doppler  imaging  during  surveillance[12-16].  Once  shunt  dysfunction  has  been
confirmed, multiple approaches may be adopted: shunt revision with angioplasty,
repeat  stenting,  deployment  of  endoprosthesis,  and/or  catheter  directed
thrombolysis[16,17].  Rarely,  a second parallel  stent (PS) can be placed to overcome
primary TIPS insufficiency and alleviate upper gastrointestinal variceal bleeding or
ascites. Here, we report a case series of PS placements in three patients with portal
hypertension secondary to alcoholic cirrhosis, alpha-1 antitrypsin deficiency (AATD),
and non-alcoholic steatohepatitis (NASH) respectively.
CASE PRESENTATION
Case 1
Chief complaints: Vomiting blood and lightheadedness.
History  of  present  illness:  A  46-year-old  female  with  alcoholic  cirrhosis  and
esophageal  varices  presented  to  the  emergency  department  (ED)  with  recent  2
episodes of hematochezia. She endorsed nausea and lightheadedness for the past few
days, denying hematemesis or coffee-ground emesis. Four months ago, she presented
with GI bleeding from esophageal varices and failed repeated esophageal bandings.
TIPS  and  coronary  vein  varices  coil-embolization  were  performed  at  that  time:
Portosystemic gradient (PSG) was reduced from 17 mmHg to 10 mmHg; direct portal
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pressure decreased from 27 mmHg to 23 mmHg. She was discharged 3 d later. During
one-month follow-up after  the procedure,  she was clinically  asymptomatic  with
adequate flow-velocities in her TIPS (Table 1).
History of past illness: Chronic pancreatitis;; non-bleeding grade 1 gastric varices
status post coronary vein coil-embolization; hypertension; endometriosis.
Personal and family history: No current tobacco, alcohol, or substance use. Family
history was non-contributory.
Physical examination upon admission:  Mildly jaundiced; abdomen was soft and
non-distended;  clear  bilateral  lung  sounds,  intact  neurological  exams  with
appropriate mood and affect.
Laboratory examinations: Hemoglobin: 4.7 g/dL and platelets: 25000/mL consistent
with anemia secondary to acute blood loss; abnormal liver function tests (Table 1).
Imaging examinations: Esophagogastroduodenoscopy (EGD) showed blood-filled
stomach  and  type-1  isolated  gastric  varices.  Contrast  enhanced  computed
tomography of the abdomen showed a blood-filled stomach and large gastric wall
varices. Four months ago, a 10 mm × 8 cm Viatorr®  (GORE, Flagstaff AR, United
States) stent was placed from right hepatic vein to the left portal vein with a 4-cm bare
metal stent extension for optimal outflow positioning into the inferior vena cava
(Figure 1A-C). Doppler ultrasound (US) demonstrated a patent stent with adequate
velocities (Table 1).
Multidisciplinary expert consult
Kinjal Dave, MD, Assistant Professor of Medicine, Division of Gastroenterology; Jen
Rosenau, MD, Assistant Professor of Medicine, Division of Hepatology.
Diagnosis
Primary TIPS insufficiency with recurrent variceal bleeding.
Treatment
Parallel TIPS placement: A TIPS revision procedure demonstrated a widely patent
stent and a portosystemic gradient of 9 mmHg. A parallel 10 mm × 8 cm Viatorr® TIPS
was inserted to manage continued bleeding, reducing PSG to 4 mmHg. The direct
portal pressure remained constant (25 mmHg) before and after the procedure. Patient
later developed urinary sepsis and was successfully treated with broad spectrum
antibiotics.
Follow-up
Six months later, patient returned to ED reporting progressive abdominal pain and
swelling. Both TIPS stents were found to be patent by US (Table 1). No ascites was
seen on US.
Case 2
Chief complaints: Persistent engorged esophageal varices on surveillance EGD.
History of present illness:  A 56-year-old male with cirrhosis secondary to AATD
status post TIPS was referred to interventional radiology (IR) in June 2017 because of
persistent  large  esophageal  varices  on  EGD.  He was  clinically  asymptomatic  at
presentation. Previously, he was admitted in April 2017 with abdominal distension,
hematemesis and acute blood loss anemia. At that time, US showed large volume
ascites and an occluded TIPS stent. In addition to paracentesis and blood transfusion,
sharp recanalization of the shunt was performed reducing PSG from 15 mmHg to 10
mmHg. He was discharged 3 d after the May 2017 admission.
History of past illness: Cirrhosis with prior esophageal variceal bleeding status post
TIPS in 2009; esophageal banding; hypertension; inguinal hernia; umbilical hernia.
Personal and family history: No tobacco, alcohol, or substance use. Family history
was positive for AATD affecting his mother’s lungs.
Physical  examination upon admission:  Jaundiced;  abdomen was  soft  and non-
distended; clear bilateral lung sounds, intact neurological exams with appropriate
mood and affect.
Laboratory examinations: Abnormal liver function tests (Table 1).
Imaging examinations: Given concern for shunt occlusion, we obviated the TIPS US
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Table 1  Laboratory values, Child-Pugh class, model for end-stage liver disease score and medications given for hepatic encephalopathy
of patient 1, 2, and 3 before the transjugular intrahepatic portosystemic shunts placement, before the parallel placement, and 6-mo
follow-up
Status Patient 1 Patient 2 Patient 3
Before TIPS Child-Pugh B; MELD 11; bilirubin
1.1, INR 1.5, PTT 18.6, albumin 2.6;
DV post TIPS: 153 (TIPS), 33 cm/s
(MPV). Lactulose 10 g/d
Child-Pugh B; MELD 11; bilirubin
0.7, INR 1.3, PTT 16.6, and albumin
3.5. Rifaximin 550 mg × 2/d,
Lactulose 20 g × 3/d
Child-Pugh C; MELD 12; bilirubin
1.6, INR 1.4, PTT 17.1, and albumin
2.5; DV immediately post-TIPS: 96
(TIPS), 89.5 cm/s (MPV). Rifaximin
550 mg × 2/d, Lactulose 30 g/45 mL
× 3/d
Before PS Child-Pugh B; MELD 15; bilirubin
4.6, INR 1.3, PTT 17.0, and albumin
2.5; DV: 155 (TIPS), 18 cm/s (MPV).
Rifaximin 550 mg × 2/d Lactulose 10
g/d
Child-Pugh B; MELD 10; bilirubin
0.7, INR 1.4, PTT 17.1, and Albumin
2.1; DV 2 wk post-PS: 147 (TIPS), 138
(PS), and 16 cm/s (MPV). Rifaximin
550 mg × 2/d, Lactulose 20 g × 3/d
Child-Pugh C; MELD 13; bilirubin
0.7, INR 1.4, PTT 17.1, and Albumin
2.5; DV: 90.9 (TIPS) 37 cm/s (MPV).
Rifaximin 550 mg × 2/d, Lactulose
(20 g) 30 mL × 3/d, Piperacillin 4.5
g/6 h
6 mo post-PS Child-Pugh B; MELD 21; bilirubin
4.5, INR 1.3, PTT 16.5, and albumin
3.5; DV: 78 (TIPS), 144 (PS), 39.3 cm/s
(MPV). Rifaximin 550 mg × 2/d
Lactulose 10 g/d
Child-Pugh B; MELD 21; bilirubin
2.5, INR 1.5, PTT 18.5, and albumin
2.8; DV: 85.8 (TIPS), 109 (PS), and 83
cm/s (MPV). Rifaximin 550 mg ×
2/d, Lactulose 20 g × 3/d
Child-Pugh C; MELD 14; bilirubin
2.1, INR 1.3, PTT 16.7, and albumin
2.0; DV: 72 (TIPS), 92 (PS), and 68
(MPV) cm/s. Rifaximin 550 mg ×
2/d, Lactulose (20 g) 30 mL × 3/d
Doppler velocities of the transjugular intrahepatic portosystemic shunts, parallel stent, and main portal vein were also measured. Laboratory values
include total bilirubin, international normalized ratio, partial thromboplastin time, and albumin. TIPS: Transjugular intrahepatic portosystemic shunts; PS:
Parallel stent; MELD: Model for end-stage liver disease; DV: Doppler velocities; MPV: Main portal vein; INR: International normalized ratio; PTT: Partial
thromboplastin time.
and proceeded immediately to TIPS revision procedure. The first Viatorr® TIPS stent
was  inserted  directly  from  the  middle  hepatic  vein.  Contrast  venography
demonstrated patency of the primary TIPS stent. The PSG was 13 mmHg despite 12-
mm balloon angioplasty.
Diagnosis
Primary TIPS insufficiency with recurrent variceal bleeding.
Treatment
Parallel TIPS placement: A 10 mm × 10 cm PS Viatorr® TIPS was inserted from right
hepatic vein to the confluence of right portal and left portal veins and coronary vein
varices were coil  embolized (Figure 2A-C).  PS reduced PSG from 13 mmHg to 7
mmHg and direct portal pressure from 34 mmHg to 21 mmHg.
Follow-up
Doppler US revealed patency in both stents during 2-wk and 6-mo follow-ups (Table
1).  In  December  2017,  patient  presented  to  ED  with  worsening  bilateral  lower
extremity edema. Whereas Doppler showed an average velocity of 121 cm/s for the
new shunt and 95 cm/s for portal vein, there was markedly decrease flow in the old
shunt with a peak velocity of 10 cm/s. IR was consulted to evaluate suspected shunt
dysfunction. However, the measured portosystemic gradient of 7 mmHg was deemed
adequate,  and contrast  flow through both stents  was  excellent.  Considering the
increased model for end-stage liver disease (MELD) score (Table 1), the patient was
evaluated  for  liver  transplant  in  February  2018  and  at  that  time,  his  follow-up
demonstrated patency of both shunts with the following velocities of 55 cm/s, 60
cm/s, and 66 cm/s for the old shunt, new shunt, and portal vein respectively.
Case 3
Chief complaints: Hematemesis.
History of present illness: A 54-year-old female with esophageal varices secondary to
NASH  cirrhosis  presented  with  hematemesis.  Initial  EGD  showed  type  2
gastroesophageal varices (GOV2) and endoscopic banding was performed. However,
the patient continued having hematemesis and was referred to IR. A 10 mm × 8 cm
Viatorr®  TIPS was  inserted from right  hepatic  vein  to  the  right  portal  vein.  The
procedure decreased PSG from 20 mmHg to 12 mmHg. Doppler US confirmed TIPS
patency (Table 1). Five days following the procedure, patient began to experience
significant hematemesis.
History of past illness:  Type 2 diabetes mellitus, hypertension, gastroesophageal
reflux  disease,  chronic  obstructive  pulmonary  disease,  umbilical  hernia,
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Figure 1
Figure 1  Imaging examinations of patient 1. A: Digital subtracted portal angiography showing successful placement of the parallel stent (red arrow) with caval
extension (yellow arrow). Embolization coils can be seen the coronary vein branches (blue arrow). Primary stent (green arrow) is seen alongside the second
transjugular intrahepatic portosystemic shunt stent. B: Maximum intensity projection with 30-mm slab of post procedural computed tomography (CT) abdomen
showing primary and parallel stents in tandem. C: 3D reconstruction of a post procedural CT abdomen showing primary and parallel stents in tandem.
hysterectomy.
Personal and family history: No tobacco, alcohol, or substance use. Family history
was non-contributory.
Physical examination upon admission: Sclera icteric; abdomen was soft and non-
distended; tachypnea, clear bilateral lung sounds, intact neurological exams with
appropriate mood and affect.
Laboratory examinations:  Hemoglobin 10.95 g/dL, white blood cells 21900/mm3,
platelets 84000/mL; abnormal Liver function tests (Table 1).
Imaging  examinations:  EGD  showed  recurrent  bleeding  from  GOV2  with  no
evidence of isolated gastric varices. Doppler US revealed TIPS patency (Table 1).
Multidisciplinary expert consult
Sara Pasha, MD, Assistant Professor of Medicine, Department of Internal Medicine-
Pulmonary Division;  Alla  Grigorian,  MD, PhD,  Assistant  Professor  of  Medicine,
Medical Director of Liver Transplant; Terrence Barrett, MD, Professor of Medicine
and Microbiology/Immunology, Chief, Division of Digestive Diseases and Nutrition.
Diagnosis
Primary TIPS insufficiency with recurrent variceal bleeding.
Treatment
Parallel TIPS placement: Due to recurrent variceal bleed and decompensated cirrhosis,
a second 10 mm × 8 cm Viatorr® TIPS was inserted from right hepatic vein to the left
portal vein (Figure 3A-C). Procedure was a technical success, decreasing PSG from 9
to 4 mmHg. Direct portal pressure decreased from 40 mmHg to 35 mmHg. Following
the  procedure,  patient  developed  hypernatremia  which  was  managed  with
intravenous fluids. Patient was discharged home seven days after.
Follow-up
Six-month US follow-up was unremarkable. Doppler demonstrated patency of both
shunts with adequate flow (Table 1).
DISCUSSION
TIPS failure  can  either  be  due  to  stent  occlusion  or  stenosis,  which  has  become
significantly less  frequent  with the widespread use of  covered stents[14,18,19].  This
complication can be diagnosed with Doppler imaging and confirmed during TIPS
revision procedure[20-24]. However, in the presence of a well-functioning primary stent,
the recurrence or persistence of ascites and variceal bleeding can be a therapeutic
challenge.  We present  a  short  case  series  to  illustrate  three  patients  with  portal
hypertension who underwent a second TIPS stent placement using Viatorr® stents.
This is commonly known as parallel TIPS (PS) or double barrel TIPS. As early as
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Figure 2
Figure 2  Treatment for patient 2. A: Digital subtracted portal angiography showing successful placement of the parallel stent (red arrow). Embolization coils can be
seen the coronary vein branches (blue arrow). Primary stent (green arrow) is seen alongside the second transjugular intrahepatic portosystemic shunts stent. B:
Maximum intensity projection with 30-mm slab of a post procedural computed tomography (CT) abdomen showing primary and parallel stents in tandem. C: 3D
reconstruction of post procedural CT abdomen showing primary and parallel stents in tandem.
1990s, the effectiveness of PS in treating shunt insufficiency had been demonstrated
along  with  other  options  such  as  re-stenting  and  balloon  angioplasty[25].  In  our
practice, PS is pursued in symptomatic patients in whom the primary TIPS shunt
insufficient or is thrombosed and recanalization techniques have failed.
In  our  case  series,  the  primary  TIPS  were  insufficient  in  alleviating  portal
hypertension  symptoms despite  their  patency  being  verified  during  follow-ups
and/or before PS placement. Furthermore, the PSGs prior to PS were below 10 mmHg
in cases 1 and 3. No laboratory values were predictive of shunt insufficiency or the
need for a PS. A study by Haskal et al[13] reported a cohort of 10 out of 93 patients that
underwent PS placement. This study alluded to insufficiency of the primary TIPS
stent in decreasing the PSG as a predictor for the need of PS placement; the mean post
procedural PSG in after the first TIPS was 10.2 ± 3.7 mmHg. In patients who received
a PS, the mean post procedural gradient was 19.1 ± 3.8 mmHg after placement of the
first  TIPS and 12.5  ±  3.5  mmHg after  placing a  PS[13].  As  the  previous  gradients
indicate, the initial TIPS were suboptimal to begin with even at maximum diameter of
10 mm expansion.
A similar trend was observed in another retrospective study, in which 40 out of 338
TIPS patients underwent parallel Wallstent® placement[26]. In this study by Helmy et
al[26], PS patients exhibited lower portal pressure gradient drop compared to single
TIPS only patients with means of (10.4 ± 5.4 mmHg vs 12.4 ± 7.1 mmHg) after the first
TIPS procedure. Whether the patients from these two studies would have benefited
from  primary  shunts  with  larger  diameters  to  begin  with  and  therefore  avoid
subsequent PS should be further investigated. In our report, single TIPS were not
sufficient for symptomatic relief despite achieving maximum stent expansion, and in
cases 1 and 3 despite optimal PSGs. This is similar to Helmy et al[26] patient cohort
requiring PS placement despite achieving a mean portal pressure gradient of 7.9 ± 4.8
mmHg after the initial shunt placement. However, as previously mentioned, his study
used bare metal stent with its inherent lower patency rate overtime.
Case  2  was  secondary  to  an  occluded  primary  TIPS,  though  it  provided  an
impressive symptom-free period of 8 years.  The successful recanalization of this
occluded shunt failed to provide symptomatic relief requiring us to place a PS to
further decrease the PSG from 13 mmHg to 7 mmHg. Also, the patient’s MELD score
increased from 10 to 21 over the following 6 mo (Table 1); on one hand, patients with
AATD tend to have rapidly progressive cirrhosis with extensive inflammation and
fibrosis  far  beyond other  causes  for  cirrhosis[27,28].  On  the  other  hand,  excessive
shunting of portal venous blood away from liver parenchyma after PS placement may
have contributed to worsening liver function. This way addressed in Helmy et al[18]
study and they advocated for the use of smaller PS to decrease the risk of hepatic
encephalopathy and mortality after PS placement.
In addition to the studies mentioned above, literature on PS is rather limited. More
recently, one group reported 18 out of 132 TIPS patients underwent PS placement
after primary TIPS stent dysfunction, indicating that shunt patency of 1-year post-PS
was higher in the patients who received Fluency® endoprosthesis than those who
received Wallgraft®  (87.5% vs  70.0%,  P  =  0.358)[29].  Another  study described the
application of  PS  in  10  cases  of  cirrhotic  patients  due to  hepatitis  B  infection[30].
Although  covered  stents  were  placed  for  both  primary  TIPS  stent  and  PS,
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Figure 3
Figure 3  Treatment for patient 3. A: Digital subtracted portal angiography showing successful placement of the parallel stent (red arrow). Primary stent (green
arrow) is perfectly parallel along the second transjugular intrahepatic portosystemic shunts stent. B: Maximum intensity projection with 30-mm slab of a post
procedural computed tomography (CT) abdomen showing primary and parallel stents in tandem. C: 3D reconstruction of post procedural CT abdomen showing
primary and parallel stents in tandem.
unfortunately, the authors did not specify the exact type and brand of stents used.
Like our cases, most primary TIPS dysfunctions were manifested by symptoms such
as ascites and recurrent variceal bleeding rather than surveillance US findings. In
addition to the PSG decease after PS placement in both studies (25.5 ± 7.3 mmHg to
10.9 ± 2.3 mmHg, and 35.60 ± 2.72 mmHg to 15.30 ± 3.27 mmHg, respectively), the
most common post procedural symptom was hepatic encephalopathy, requiring only
medical management with Lactulose and Rifaximin, which were also prescribed for
all our patients (Table 1). With average follow-ups of 16.7 ± 10.8 mo and 14.0 ± 1.13
mo, these two studies reported adverse outcomes including worsening liver function,
recurrent variceal bleed and death. In comparison, our case series of PS achieved
patency at 6-mo follow-up. However, only patient 1 and 3 from our report remained
symptom  free  post-PS  for  those  6  mo,  while  patient  2  developed  progressive
worsening of  hepatic  function,  likely a combination of  ATTD progression of  the
disease and excessive portal blood shunting away from liver parenchyma. In terms of
portal hypertensive symptoms, PS successfully prevented recurrent variceal bleeding
and ascites in all 3 cases for at least 6-mo follow-up.
A pre-procedural review of abdominal cross-sectional imaging and of the initial
TIPS procedure  can assist  in  optimal  planning of  PS  placement.  For  the  patient
discussed in case 2, the initial TIPS was placed from the middle hepatic vein to the
right main portal vein. This left us ample space for placement of the second TIPS from
the right hepatic vein to the left portal vein. As for cases 1 and 3, the first TIPS was
placed from the right hepatic vein to the right portal vein. In each case, the origin of
the right hepatic vein was peripheral enough into the liver to allow for a new access of
the right hepatic vein for a subsequent PS placement into the left portal vein. Overall,
placement of a second TIPS stent is not technically challenging after careful review of
the hepatic venous anatomy and of the target portal venous branch. The left portal
vein can be accessed from the hepatic vein aided by a more acute angle of the TIPS
needle to allow a more anterior reach and can be easily targeted from either the right
or the middle hepatic veins. We typically avoid placing a PS within the same portal
vein of the primary stent to avoid a crowded space that would limit stent expansion.
Shunt reduction maybe performed if needed to address medically uncontrollable
hepatic encephalopathy, however, this was not observed in our series.
Despite the widespread use of Viatorr® stents in TIPS placement for over 20 years,
there are only two reports of use of primary and PS Viatorr® stents placement with
limited follow-up data. The first of which is a single case report describing the use of
Viatorr®  stent for both primary TIPS and PS in an alcoholic cirrhotic patient that
initially presented with recurrent variceal bleeding after being lost to follow-up for 3
years[31].  Similar  to  cases  1  and  3,  his  PSG  was  as  low  as  10  mmHg  prior  to  PS
placement and was then reduced to 5 mmHg post-PS. Unfortunately; the authors did
not provide clinical or imaging follow-up data. Another case report of two cases
described the successful placement of primary and parallel Viatorr® stents in recurrent
hydrothorax and ascites  respectively.  In  both instances  the PSG at  the time was
suboptimal at ≥ 12 mmHg prior to PS placement, but with no radiological evidence of
primary stent dysfunction. The only follow-up data provided was clinical resolution
of  hydrothorax and ascites  at  two and three  months  respectively.  No follow-up
Doppler US data was provided on these shunts[23].
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In our case series, all patients underwent Viatorr® PS placement for recurrent upper
gastrointestinal variceal bleeding despite adequate PSG in two out of three cases.
Also, we were fortunate to have follow-up data showing technical and clinical success
of up to 6 mo including Doppler US velocities of primary and PS shunts.
To our knowledge, we are the first to report a three-case series with 6-mo follow-up
data, using Viatorr® for both primary TIPS and PS placement for the management of
recurrent upper gastrointestinal variceal hemorrhage. Patients after TIPS placement
should be monitored routinely using Doppler US of the stents to avoid TIPS stent
occlusion.  Previous  studies  recommend US follow-up every  3-12  mo after  TIPS
procedure[18]. Within our institution, shunt patency evaluations are performed at 3 mo,
6 mo, 1 year and yearly thereafter. A mean shunt velocity < 90 cm/s or > 200 cm/s, or
a value lower than 30 cm/s in the main portal vein should raise the suspicion of shunt
dysfunction[18]. TIPS catheter venography and PSG are performed in patients with
suspicious US findings and/or in those with persistent portal hypertensive symptoms
despite US evidence of a well-functioning primary TIPS. We pursue a PS in patients
with either a non-salvageable primary TIPS or with symptom persistence despite a
well-functioning primary TIPS.
CONCLUSION
In conclusion, the addition of a second Viatorr® TIPS stent to a preexisting primary
TIPS stent in patients with recalcitrant upper gastrointestinal variceal hemorrhage
after a single Viatorr® stent placement proves insufficient in the control of variceal
bleeding despite maintaining adequate patency, is feasible and has promising short
term follow-up data. These findings are supported by Haskal et al[13] retrospective data
on the role of parallel TIPS stents for primary TIPS insufficiency. And while Haskal’s
study used bare metal stents, Bureau et al[19] randomized controlled trial from 2004
supported the superiority and safety of several covered stents over bare metal stents
when  placed  as  a  primary  TIPS.  Hence,  considering  the  added  design  specific
advantages of Viatorr®  stents when placed as the primary TIPS, their therapeutic
value in treating recurrent variceal bleeding after primary shunt insufficiency should
be investigated further with a prospective data that addresses this unique cohort of
patients  in  need  of  parallel  TIPS  stents  for  adequate  control  of  their  portal
hypertension.
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